The metabolism and pharmacokinetics of phospho‐sulindac (OXT‐328) and the effect of difluoromethylornithine

@article{Xie2012TheMA,
  title={The metabolism and pharmacokinetics of phospho‐sulindac (OXT‐328) and the effect of difluoromethylornithine},
  author={G. Xie and T. Nie and G. Mackenzie and Y. Sun and L. Huang and N. Ouyang and N. Alston and C. Zhu and O. T. Murray and P. Constantinides and L. Kopelovich and B. Rigas},
  journal={British Journal of Pharmacology},
  year={2012},
  volume={165}
}
BACKGROUND AND PURPOSE Phospho‐sulindac (PS; OXT‐328) prevents colon cancer in mice, especially when combined with difluoromethylornithine (DFMO). Here, we explored its metabolism and pharmacokinetics. 
View on Wiley
europepmc.org
18 Citations
Highly Influential Citations
1
Background Citations
13
Methods Citations
4
Results Citations
2

18 Citations

Citation Type

Citation Type

Regioselective oxidation of phospho‐NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety
The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.
In Vitro and In Vivo Metabolic Studies of Phospho-aspirin (MDC-22)
cacy of topical P-S hydrogel in the treatment of non-melanoma skin cancer in preclinical models. P-S is a potent inhibitor of A431 epidermoid carcinoma in vitro and achieves this effect by inhibiting cell proliferation and inducing apoptosis
  • 2012
Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer
The ocular pharmacokinetics and biodistribution of phospho‐sulindac (OXT‐328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery
Aerosol Administration of Phospho-Sulindac Inhibits Lung Tumorigenesis
Phospho-Sulindac (OXT-328) Inhibits the Growth of Human Lung Cancer Xenografts in Mice: Enhanced Efficacy and Mitochondria Targeting by its Formulation in Solid Lipid Nanoparticles
Phospho-NSAIDs Have Enhanced Efficacy in Mice Lacking Plasma Carboxylesterase: Implications for their Clinical Pharmacology
Development of oseltamivir phosphonate congeners as anti-influenza agents.
...
1
2
...

References

SHOWING 1-10 OF 51 REFERENCES
Phospho-Sulindac (OXT-328) Combined with Difluoromethylornithine Prevents Colon Cancer in Mice
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide.
The novel phospho‐non‐steroidal anti‐inflammatory drugs, OXT‐328, MDC‐22 and MDC‐917, inhibit adjuvant‐induced arthritis in rats
The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Antiinflammatory Drugs (Nsaids)
Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations
Phospho-Ibuprofen (MDC-917) Is a Novel Agent against Colon Cancer: Efficacy, Metabolism, and Pharmacokinetics in Mouse Models
  • G. Xie, Y. Sun, +5 authors B. Rigas
  • Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
  • 2011
Synthesis and biological identification of the acyl glucuronide of the antiinflammatory drug ML-3000
In Vitro Metabolism of Nitric Oxide-Donating Aspirin: The Effect of Positional Isomerism
Effect of Carboxylesterase Inhibition on the Anti-Tumour Effects of Irinotecan
...
1
2
3
4
5
...